Role of Doppler Ultrasound in Severe Peptic Ulcer Hemorrhage

Sponsor
Chinese University of Hong Kong (Other)
Overall Status
Terminated
CT.gov ID
NCT00164905
Collaborator
University Hospitals Cleveland Medical Center (Other)
121
1
2
71
1.7

Study Details

Study Description

Brief Summary

The aim of study is to evaluate whether Doppler ultrasound can accurately identify patients who are at risk of recurrent bleeding, who will require endoscopic therapy, and who will fail endoscopic therapy.

Condition or Disease Intervention/Treatment Phase
  • Device: Doppler ultrasound probe
N/A

Detailed Description

Bleeding peptic ulcer is a life-threatening emergency. Endoscopic therapy is a proven technique in the acute hemostasis of bleeding ulcers. Currently there is no objective assessment of adequacy of endoscopic therapy. Endoscopic Doppler ultrasound enables endoscopists in detecting blood flow in a vessel beneath an ulcer. A persistent signal after endoscopic therapy predicts recurrent bleeding. The current study proposes to compare assessment of ulcer base using either Doppler ultrasound or endoscopists' interpretation of ulcer floors. The trial design is one of a prospective randomized controlled cross-over study in which patients with severe upper gastrointestinal bleeding and documented peptic ulcers at endoscopy are enrolled.

Study Design

Study Type:
Interventional
Actual Enrollment :
121 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
Single (Participant)
Primary Purpose:
Treatment
Official Title:
Role of Doppler Ultrasound in Severe Peptic Ulcer Hemorrhage: Can it Guide the Use of and Predict Failure of Endoscopic Treatment? A Prospective, Multicenter, Randomized, Controlled Study
Study Start Date :
Sep 1, 2004
Actual Primary Completion Date :
Aug 1, 2010
Actual Study Completion Date :
Aug 1, 2010

Arms and Interventions

Arm Intervention/Treatment
Active Comparator: Doppler ultrasound

Device: Doppler ultrasound probe
Applying to ulcer base to assess the blood flow underneath the ulcer
Other Names:
  • DOP_US
  • No Intervention: No Doppler ultrasound

    Outcome Measures

    Primary Outcome Measures

    1. Recurrent bleeding [Within 30 days]

    Secondary Outcome Measures

    1. Length of stay [Within 56 days]

    2. ICU utilization [Within 56 days]

    3. Blood Transfusion during hospital [Within 56 days]

    4. Need for urgent/emergent ulcer surgery for bleeding [Within 56 days]

    5. Need for angiographic treatment of bleeding [Within 56 days]

    6. Death [within 56 days]

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    18 Years and Older
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    No
    Inclusion Criteria:
    • Clean base ulcer with severe upper GIB (defined as melaena, hematochezia, hematemesis, and/or gross blood in NG lavage), and any one of the following:
    1. SBP ≤ 90mmHg; P of ≥110 bpm; or orthostatic changes with SBP drops 20mmHg or P increases 20 bpm; or,

    2. Transfusion of 2 or more units of packed red blood cells within 12 hrs of admission; or,

    3. A documented HCT drop of at lest 6% from baseline.

    • Endoscopically confirmed bleeding from GU, DU, pyloric ulcer, or anastomotic ulcer

    • Pt can either have primary or secondary acute UGI haemorrhage

    Exclusion Criteria:
    • Bleeding site from lesion other than GU, DU, pyloric or anastomotic ulcer

    • there is more than one type of significant bleeding lesion

    • Documented hx of cirrhosis / portal HT

    • ESRF requiring any form of dialysis

    • Expected or persistent (>24hrs) coagulopathy with INR> 1.5

    • Platelet count is under 50000/mm3

    • Aspirin User / Plavix [Clopidogrel] User

    • If the ulcer is neoplastic

    • Cannot obtained consent

    • Age < 18 or is pregnant

    • Severe comorbid of which life expectancy <30 days

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 Endoscopy Center, Prince of Wales Hospital Hong Kong SAR China

    Sponsors and Collaborators

    • Chinese University of Hong Kong
    • University Hospitals Cleveland Medical Center

    Investigators

    • Principal Investigator: James Y Lau, MD, Prince of Wales Hospital

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    None provided.
    Responsible Party:
    James Yun-wong Lau, Professor, Chinese University of Hong Kong
    ClinicalTrials.gov Identifier:
    NCT00164905
    Other Study ID Numbers:
    • DOP-US study
    First Posted:
    Sep 14, 2005
    Last Update Posted:
    Aug 28, 2012
    Last Verified:
    Aug 1, 2012
    Keywords provided by James Yun-wong Lau, Professor, Chinese University of Hong Kong
    Additional relevant MeSH terms:

    Study Results

    No Results Posted as of Aug 28, 2012